Skip to content

Public FDA record

Z-2281-2023: Impella RP Flex with SmartAssist intracardiac microaxial blood pump, Product Number 1000323

Recall record Z-2281-2023 for Abiomed, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-2281-2023
Company in FDA record
Abiomed, Inc.
FDA classification date
Aug 3, 2023
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class I

Reason stated in the source

A higher than expected rate of thrombus formation or deposition has been observed. The risk is for thrombus formations or deposits on indwelling central venous lines or cannulas may break free and enter into the Impella RP Flex, resulting in reduced flow, loss of support, or hemolysis

Source facts

Action
An URGENT: MEDICAL DEVICE CORRECTION (NOTIFICATION) letter dated 6/29/23 was sent to customers. RECOMMENDATIONS: To minimize risk of thrombus formation or deposition, the following is recommended: " Maintenance of systemic anticoagulation (ACTs of 160-180 seconds) in particular when indwelling central venous lines (i.e., hemodialysis, PA catheters) are present, for the duration of Impella RP Flex with SmartAssist support as clinically feasible. " Assess the risk for extraluminal thrombus on indwelling lines (i.e., hemodialysis catheters, PA catheters) placed prior to initiation of support. " Users are reminded of the recommendations included in the best practices pathway on Figure 5.2 of IFU for optimal patient selection. In particular, elements that relate to the risk factors identified above: o Evidence of end-organ failure (bilirubin >5 or creatinine >4 within 24 hrs of implant) o Active infection (two of the following three: White Blood Cell (WBC) count >12,500, positive blood culture or fever) o Documented Deep Vein Thrombosis (DVT) o Patients on right-sided support or Extracorporeal Membrane Oxygenation (ECMO) Abiomed is revising the IFUs for the Impella RP Flex with SmartAssist to clarify the risk factors and recommendations related to the potential of thrombus formation or deposition. ACTIONS TO BE TAKEN BY CUSTOMER/USER " Product is NOT being removed from the field and does not need to be returned. " Review, complete all fields, sign, and return the attached business response form (BRF) on the last page of this letter to the Recall Coordinator identified in this document. Forward this notice to anyone in your facility that needs to be informed (i.e., those who manage, transport, store, stock, or use the subject products). " If any of the subject products have been forwarded to another facility, contact that facility and provide them with this notice. " Post a copy of this notice in a visible area for awareness of this field safety notice. " Follow th
Initiated
2023-06-29
Root cause
Under Investigation by firm
Distribution
US Nationwide distribution including in the states of AR, CA, FL, GA, LA, MA, MI, MO, NC, NJ, NY, OH, OR, SC, TX, and WI.
Recall number
Z-2281-2023
Recall status
Open, Classified
CDRH record ID
200858
FDA classified
2023-08-03
Recall event number
92411

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗